Tourmaline Bio EBIT

Tourmaline Bio (TRML) currently reports a EBIT of $-100M as of June 2025. That compares with $-55M in the prior-year period — down 87.9% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Tourmaline Bio's EBIT history and peer comparisons.

Tourmaline Bio's EBIT decreased from $-55M to $-100M — a 87.9% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Tourmaline Bio's EBIT of $-100M is lower than the Healthcare sector average of $23B. That is roughly 100.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Tourmaline Bio reported $-100M in EBIT as of June 2025. That compares with $-55M in the prior-year period — down 87.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-100M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Tourmaline Bio, and consider following TRML for alerts when major investors trade the stock.